This is important to note because epigenetic silencing of the MGMT promoter via methylation impairs the repair of DNA damage caused by temozolomide, thereby conferring improved survival outcomes in patients with glioblastoma compared to those patients without MGMT promoter methylation [37]. The gene discussed is MGMT; the disease is glioblastoma.